Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a lik

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the st

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront paym

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the di

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a B

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR

BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the

Jefferies analyst Roger Song maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the pri

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Ph

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in

Agreement offers potential best-in-class targeted protein degrader therapy option for people living

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a B

The presentations highlight continued progress across Nurix's oncology pipeline, including progr

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a B

Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight an

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.79) per share which beat the analy

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a B

Piper Sandler analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweig

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform a

Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises th

Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight an

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Bu

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2

Morgan Stanley analyst Terence Flynn upgrades Nurix Therapeutics (NASDAQ:NRIX) from Equal-Weight

Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight an

Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Bu

BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a st

Truist Securities analyst Gregory Renza assumes Nurix Therapeutics (NASDAQ:NRIX) with a Buy ratin

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing target

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains